Cocrystal's CDI-988 is a new oral drug that may prevent/treat norovirus, the stomach bug. It targets a viral enzyme, shows broad-spectrum activity & good safety in early studies. FDA approved next study for this potential first-of-its-kind antiviral.
Centene's shares jumped! They confirmed profit goals, got good Medicare ratings, & saw better Medicaid costs. This signals a positive turnaround for the health insurer, easing investor worries.
Amneal Pharmaceuticals receives FDA approval for its generic sodium oxybate, offering a more accessible and cost-effective treatment for narcolepsy's excessive sleepiness and cataplexy in patients 7+.
New IPF drug GRI-0621 shows no lung decline at 6 weeks and anti-fibrotic effects in early studies. It's safe and well-tolerated. This offers hope for IPF patients, as current treatments are limited. Full results expected Q3 2025.
Tempus AI's FDA-cleared Pixel update uses AI to analyze heart MRI scans, generating detailed tissue maps to detect hidden issues like fibrosis, helping doctors provide more precise, personalized care.
AbbVie secured a "big win," delaying generic Rinvoq until April 2037 by settling lawsuits. This extends the drug's market run significantly, much longer than expected, boosting company value and helping offset declining Humira sales.
